Philadelphia Court of Common Pleas Judge Arnold L. New has ordered two Risperdal cases to proceed in a new trial for punitive damages. In both cases, causation and compensatory damage were already awarded the

Stephen and Sandra Sheller were honored July 13, 2018 at the Salvation Army’s “Celebration of Philanthropy” event announcing the new Stephen and Sandy Sheller Emergency Disaster Service Command Center. The command center was

The PA Supreme Court has agreed to review a Superior Court decision which would dismiss thousands of Risperdal cases due to statute of limitations. The two cases on appeal, Saksek v. Janssen and Winter v. Janssen,

Juries across the country have been handing down “eye catching” verdicts for plaintiffs with ovarian cancer and their families against Johnson & Johnson. The most recent included a nearly $4.7 billion verdict for

Philadelphia Court of Common Pleas Judge Paula Patrick urges the Pennsylvania Superior Court to uphold the $70 Million jury verdict in A.Y. v. Janssen Pharmaceuticals. AY is one of many boys who developed

As the nation’s opioid crisis continues 162 of the 600 people recently charged with healthcare fraud were healthcare professionals who contributed to the nation’s fastest and most deadly epidemic. Conducted nationwide, this was the largest

Super Lawyers has again recognized the attorneys of Sheller P.C. in 2018. Founder Stephen A. Sheller has been selected by the organization for the fifteenth consecutive year. Attorneys Kimberly A. Aponte Borden and Jamie

Sheller PC’s founder, Stephen Sheller, joined other litigators, judges and state prosecutors at a conference to discuss the legal response to the opioid crisis. The forum was hosted by University of Pennsylvania Law

Stephen A. Sheller, who has served on the board of trustees of Drexel University since 2003 and on Drexel’s Thomas R. Kline School of Law advisory board, will receive an honorary degree at

More than 100 states, cities, counties and other public entities have filed opioid-related lawsuits against the drug manufacturers in 2017. The lawsuits being filed continue into 2018 including the city of Philadelphia who